Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
SLAS Discov ; 29(5): 100170, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38964171

ABSTRACT

The importance of a drug's kinetic profile and interplay of structure-kinetic activity with PK/PD has long been appreciated in drug discovery. However, technical challenges have often limited detailed kinetic characterization of compounds to the latter stages of projects. This review highlights the advances that have been made in recent years in techniques, instrumentation, and data analysis to increase the throughput of detailed kinetic and mechanistic characterization, enabling its application earlier in the drug discovery process.


Subject(s)
Drug Discovery , High-Throughput Screening Assays , Drug Discovery/methods , Kinetics , High-Throughput Screening Assays/methods , Humans , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/metabolism , Structure-Activity Relationship
2.
J Med Chem ; 65(20): 13879-13891, 2022 10 27.
Article in English | MEDLINE | ID: mdl-36200480

ABSTRACT

Human DNA polymerase theta (Polθ), which is essential for microhomology-mediated DNA double strand break repair, has been proposed as an attractive target for the treatment of BRCA deficient and other DNA repair pathway defective cancers. As previously reported, we recently identified the first selective small molecule Polθ in vitro probe, 22 (ART558), which recapitulates the phenotype of Polθ loss, and in vivo probe, 43 (ART812), which is efficacious in a model of PARP inhibitor resistant TNBC in vivo. Here we describe the discovery, biochemical and biophysical characterization of these probes including small molecule ligand co-crystal structures with Polθ. The crystallographic data provides a basis for understanding the unique mechanism of inhibition of these compounds which is dependent on stabilization of a "closed" enzyme conformation. Additionally, the structural biology platform provided a basis for rational optimization based primarily on reduced ligand conformational flexibility.


Subject(s)
DNA End-Joining Repair , Poly(ADP-ribose) Polymerase Inhibitors , Humans , Ligands , DNA/metabolism , DNA Polymerase theta
SELECTION OF CITATIONS
SEARCH DETAIL